Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician

Lancet Neurology
Aaron BosterMultiple Sclerosis Clinical Research Center, Department of Neurology, Wayne State University School of Medicine

Abstract

Several lines of evidence link immunosuppression to inflammation in patients with multiple sclerosis (MS) and provide a rationale for the increasing use of immunosuppressive drugs in the treatment of MS. Treatment-refractory, clinically active MS can quickly lead to devastating and irreversible neurological disability and treating these patients can be a formidable challenge to the clinician. Patients with refractory MS have been treated with intense immunosuppression, such as cyclophosphamide or mitoxantrone, or with autologous haematopoeitic stem cell transplants. Evidence shows that intense immunosuppression might be effective in patients who are unresponsive to immunomodulating therapy, such as interferon beta and glatiramer acetate. Natalizumab, a new addition to the armamentarium for treating MS, might also have a role in the treatment of this MS phenotype. This Review describes the use of intense immunosuppressant drugs and natalizumab in patients with rapidly worsening MS and provides clinicians with guidelines for the use of these drugs in this patient group.

References

Aug 6, 1973·JAMA : the Journal of the American Medical Association·B M BerksonI Shapiro
Jan 21, 1997·Proceedings of the National Academy of Sciences of the United States of America·K E BalashovH L Weiner
Jun 9, 1999·Annals of Neurology·C L Karp
Nov 18, 2000·Journal of Neurology·P MandalfinoG C Ebers
Apr 5, 2001·Brain : a Journal of Neurology·S H AlusiP G Bain
Jun 13, 2001·Neurology·UNKNOWN Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group
Jun 27, 2002·Neurology·T H BrannaganD E Gladstone
Sep 11, 2002·Neurology·J A CohenUNKNOWN IMPACT Investigators
Dec 31, 2002·Lancet·Hans-Peter HartungUNKNOWN Mitoxantrone in Multiple Sclerosis Study Group (MIMS)
Nov 24, 2004·Neurology·L KapposUNKNOWN North American (NA-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Indepen
Dec 30, 2004·Neurology·B A CohenH Zwibel
Feb 5, 2005·Acta Neurologica Scandinavica·P R M de Bittencourt, M M Gomes-da-Silva
Jul 13, 2006·Archives of Neurology·Bianca Weinstock-GuttmanRohit Bakshi
Jan 19, 2007·Journal of Neurology, Neurosurgery, and Psychiatry·F PaulF Zipp
Apr 12, 2007·Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging·Federica Agosta, Massimo Filippi
Apr 21, 2007·Current Treatment Options in Neurology·Adrienne Boissy, Robert J Fox

❮ Previous
Next ❯

Citations

Mar 28, 2009·Journal of Neurology·Andrew ChanNicolas von Ahsen
Jan 8, 2013·Journal of Neurology·Ludwig KapposChristophe Hotermans
Oct 4, 2008·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Mauro ZaffaroniGiancarlo Comi
Oct 4, 2008·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Mark S Freedman
Sep 24, 2009·Neurocritical Care·Logan M McDaneldAnish Bhardwaj
Jan 1, 2014·Clinical Neurology and Neurosurgery·Silvia N Tenembaum
Jun 10, 2010·Nature Reviews. Neurology·Michal Schwartz, Ravid Shechter
Oct 24, 2008·The New England Journal of Medicine·Stephen L Hauser
Sep 23, 2008·Multiple Sclerosis : Clinical and Laboratory Research·E IacobaeusEo Major
Nov 1, 2008·Therapeutic Advances in Neurological Disorders·Peter RieckmannJoel Oger
Jul 4, 2009·Nanomedicine·Ari NowacekHoward E Gendelman
Dec 18, 2013·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Yingjuan LuChristopher P Leamon
May 7, 2011·Autoimmune Diseases·Francesco Patti, Salvatore Lo Fermo
Jan 8, 2013·European Journal of Medicinal Chemistry·Naveen MulakayalaSrinivas Oruganti
Jun 15, 2013·La Revue de médecine interne·R DepazO Gout
Nov 19, 2010·International Immunopharmacology·Fang ZhouAbdolmohamad Rostami
Aug 21, 2010·The American Journal of Pathology·Jingxian YangGuang-Xian Zhang
May 18, 2010·Clinical Neurology and Neurosurgery·Silvia N Tenembaum
Sep 9, 2008·Drug Discovery Today·Georg PilzJörg Kraus
Oct 19, 2013·Clinical and Experimental Immunology·A WinkelmannU K Zettl
Nov 20, 2009·Clinical and Experimental Immunology·K ManganoF Nicoletti
Aug 14, 2015·Der Nervenarzt·P KolberF Zipp
Jul 16, 2010·Expert Opinion on Biological Therapy·Ashley BivinsFadia T Shaya
Jun 29, 2010·Journal of the Neurological Sciences·Kenkichi Nozaki, Nada Abou-Fayssal
Aug 17, 2011·Multiple Sclerosis : Clinical and Laboratory Research·R Le BoucP Vermersch
Jun 5, 2013·Nature Reviews. Neurology·Teresa C FrohmanElliot M Frohman
Jun 21, 2018·Journal of Neurology, Neurosurgery, and Psychiatry·Jing ChenIngrid A F van der Mei
Nov 7, 2008·Expert Review of Neurotherapeutics·Ralf A LinkerRalf Gold
Sep 10, 2020·Molecular Pharmaceutics·Matthew A ChristopherCory J Berkland

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.